Clinical trial NCT01295619: Performance and Safety of I-020805 in Prevention of Cerebrospinal Fluid (CSF) Leakage Following Elective Craniotomy
Official title: A Prospective, Open, Multi-center, Single-arm Study of the Performance and Safety of I-020805 in the Prevention of Cerebrospinal Fluid Leakage Following Elective Cranial Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cerebrospinal Fluid Leakage
Keywords: Dura
Sealant
Cranial
Craniotomy
CSF leakage
CSF leakage following cranial surgery
Lead sponsor: Kuros Biosurgery AG
Sponsor class: INDUSTRY
First posted: 2011-02-14
Enrollment: 41
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This is a prospective study to evaluate the performance and safety of a new medical device used in case of cerebrospinal fluid (CSF) leakage after an elective cranial surgery.

Detailed description: Patients who consented to participate in the trial and fulfilled the preoperative inclusion and exclusion criteria underwent screening prior to surgical treatment. After dural suturing, if patients met the intra operative inclusion and exclusion criteria, they received I-020805. If necessary, autologous grafts were to be used to augment dural closure.

I-020805 was delivered from a double syringe applicator that creates a fine layer over the dura. This layer quickly sets within seconds to form a watertight seal.

Eligibility criteria: Inclusion Criteria:

Pre-operative

* Male or female of 18 years old or over
* Elective cranial procedure entailing a dural incision of at least 2 cm in length
* Requires a procedure involving surgical wound classification Class I/Clean
* Signed informed consent form
* Negative pregnancy test at screening for women of childbearing potential and agreeing to use an acceptable birth control method or abstinence until 90 days post-surgery

Intra-operative

* Surgical wound classification Class I/Clean
* Dural margin from bony edges of at least 3 mm throughout
* Spontaneous expression of CSF assessed visually or a CSF leakage upon Valsalva maneuver

Exclusion Criteria:

Pre-operative

* Cranial procedure requiring translabyrinthine, transoral and/or any procedure penetrating the air sinus or mastoid air cells
* Presence of symptomatic hydrocephalus
* Pre-existing external ventricular drainage or lumbar CSF drain
* Radiotherapy in the planned surgical region which ended within 3 months prior to planned surgery
* Presence of systemic infection
* Known history of hemophilia or other clinically significant coagulopathy
* Known oral anticoagulant use
* Pregnancy or breast feeding
* Known allergy to any components of I-020805
* Previous participation in this trial or any investigational drug or device study within 30 day of screening
* Known clinically significant organ or systemic diseases
* Known or suspected non-compliance with trial procedures

Intra-operative

* Patient not meeting the pre-operative eligibility criteria
* Not able to tolerate a Valsalva maneuver
* Gap of more than 2 mm remaining after primary closure of dura
* Use of synthetic or non-autologous duraplasty material

Primary outcomes:
measure: Performance of I-020805 in prevention of CSF leakage
timeFrame: Intraoperative on the day of sugery
Secondary outcomes:
measure: Incidence of CSF leakage
timeFrame: Within 7 days after surgery or prior to discharge
measure: CSF leakage or pseudomeningocele related surgical intervention
timeFrame: Within 90 days following surgery
measure: CSF leakage confirmed by clinical evaluation or diagnostic testing
timeFrame: Within 90 days following surgery
measure: Surgical infection and unexpected neurological signs
timeFrame: Post-operative and within 7 days and 90 following surgery
measure: Wound healing impairment
timeFrame: Throughout study up to 90 days following surgery
measure: Incidence of all and treatment emergent adverse events
timeFrame: Throughout study up to 90 days following surgery
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Charite Universitätsmedizin (01)
city: Budapest
country: Hungary
facility: Orszagos Idegtudomanyi Intezet (11)
city: Debrecen
country: Hungary
facility: Debreceni Tudomanyegyetem (12)
city: Szeged
country: Hungary
facility: Szegedi Tudomanyegyetem (10)
Study officials:
affiliation: Kuros Biosurgery
name: Virginia Jamieson, MD
role: STUDY_DIRECTOR
References: